ESAP™ 2015 Endocrine Self-Assessment Program Questions&Answers Discussions Endocrine Society

209 Pages·2015·4.125 MB·English

ESAP™2 015
EndocrSioncei ety's
EndocrSienlef -AssesPsrmoegnrta m
QuestioAnnss,w erasn,dD iscussions
AlanC .C alkiMnD,, P rograCmh air
ProfesosfoM re dicine
DivisoifoE nn docrinoalnodMg eyt abolism
UniverosfiV tiyr ginia
ShehzaSd. B asariMaD, JamesW .F indliMnDg , SuzannMe. J and eB eurM,D
Associate ProoffMe esdsiocri ne ProfesosfoM re dicine AssociPartoef esosfoM re dicine
MedicDailr ecSteocrt,i oonnM en's MedicCaoll leogfeW isconsin JohnHso pkiUnnsi vseirStyc hooolfM edicine
HealtAhg,i nga,n dM etabolism ChieDfi,v isoifoE nn docrinology,
Brighaamn dW omen'Hso spital Pamela FredaM,D Diabetaensd,M etabolism
U.
HarvaMredd icSaclh ool ProfesosfMo erd iciantCe U MC JohnHso pkiBnasy viMeewd icCaeln ter
ColumbUinai versCiollteyg,oe f
KristiBeone laerMtD, PhysiciaanndSs u rgeons JacqueliJnoen klaaMsD,, P hD
CentefroE rn docrinolDoigay,b etes, AssociPartoef essor
andM etabolism MarieF reeMlB,, C hB,P hD DivisoifoE nn docrinoalnodMg eyt abolism
UniverosfiB tiyr mingham SeniLoerc tuirneE rn docrinology GeorgetoUwnni versity
InstiotfuC taer diovasacnudl ar
MariLa. C ollazo-CiaMvDe ll, MedicSacli ences LisRa .T annockM,D
Associate ProfMeesdsiocri noef Associate ProofMf eedsiscoirn e
UniverosfiG tlya sgow
MayoC linCiocl leogfeM edicine ChieDfi,v isoifoE nn docrinoalnodg y
Molecular Medicine
JennifGerre enM,D
KathryMnc CrystDaalh irM,D UniverosfiK teyn tucaknyd
Associate ProoffMe esdsiocri ne
AssistParnotf esosfoM re dicine DepartmoefnV te terAaffnsa irs
DivisoifoE nn docrinoMleotgayb,o lism,
DivisoifoE nn docrinology
andN utrition
VanderUbniilvte rMseidtiyc Caeln ter AdrianV ellMaD,
DukeU niverMseidtiyc Caeln ter V.
ProfessoofrM edicine
ThomasW .D onnerM,D MayoC linCiocl leogfeM edicine
ShubhadJaa gasiMaD,, M MHC
AssociPartoef esosfoM re dicine
ProfesosfoM re dicine
DivisoifoE nn docrinology, CorrinWee ltM,D
AssociDaitree cotfCo lri nAiffcaali rs
Diabetaensd,M etabolism ProfesosfoM re dicine
DivisoifoE nn docrinoDlioagby,e tes,
JohnHso pkiUnnsi versity UniverosfiU ttya Shc hooolfM edicine
andM etabolism
VanderUbniilvte rMseidtiyc Caeln ter
AbbieL .Y oungM,S ,C GC,E LS(D)
MedicEadli tor
�,
EndocriSnoec iety ENDOCRINE
2055L StreNeWt, S uit6e0 0W,a shingtDoCn 2,0 036
SOCIETY-•
1-888-ENDOCR• IwNwEw .endocrine.org
HormonSec ientcoHe e alth
TheE ndocrSioncei eitsty h ew orldl'asr geosltd,e satn,dm osta ctiovreg anization
workitnoga dvancthee clinipcraalc toifce en docrinoalnodhg oyr monree search.
Foundeidn1 916t,h eS ocientoyw h asm oret ha1n8 ,00g0l obmaelm berasc rosas
rangoefd isciplTihneeS so.c iehtayse arneadni nternational froeerxp cuetlalteinocne
int heq ualoift yi ptese-r reviewjeodu rnaeldsu,c atiroensaolu rcmeese,t inagnsd,
progratmhast i mpropvueb lhieca ltthhr outghhep ractaincdes cienocfee ndocrinology.
Visiutsa t: OthePru blications:
education.endocrine.oprrge ss.endocrine.org
endocrine.org
Thes tatemeanntdos p inieoxnpsr essientd h ipsu blicaatrieto hno soeft hein dividual
authoarnsdd on otn ecessarreifllyte hcevt i ewosft heE ndocrSioncei eTthye.E ndocrine
Socieitsny o tr esponsoirbl liea bilnae n yw ayf otrh ec urrenocfthy e informaftoiaron ny,
erroormsi,s sioonris n,a ccuraocrif oearsn ,y c onsequences arisinWgi tthh erefrom.
respetcoat n yd rugmse ntiontehder, e adiesra dvsiedt or efteorth e appropriate
mediclailt eraatnudtr heep roduincfto rmatciuornr enptrloyv idbeytd h em anufacttuor er
veriafpyp roprdioastaeg mee,t hoadn dd uriaotno fa dministraantdoi tohne,rr e levant
informatIni oanlil.n stanicitess t ,h er esponsiobfti hleitt rye atpihnygs icoirao nt her
healctahr per ofessiroenlayloi,nn i gn dependeexnpte rieanncdee x pertaissw ee,la ls
knowledogfte h ep atietnodt e, teirnmet heb esttr eatmfeontrth ep atient.
PERMISSIONS:F orp ermisstioro enu smea teripalle,a saec cess
http://www.copyorric gohntt.atcchotemC o pyrhitCg learanCecnet eIrn,c( C.C C),
222R osewooDdr ivDea,n verMsA, 0 19239,7 8-7-580400C.C C isa non-fo-prroitf
organizatthiapotrn o vidleisc enasnedsr egistrfaotariv oanr ieotfuy s esF.o rm ore
informaitnidoin,v iodrui anls tituptuirohcansaels p,l eacsoen taScotc ieSteyr vicbeys
telephaotn2 e0 2-971-3646o r8 88-363-6762e;-m aisle,r vice@endocroirvn ies.iotr g;
theo nlisnteo raetw ww.endocrine.org/store.
TRANSLTAIONS ANDL ICENSING:R ighttost ranslaantdre e produEcned ocrine
Socieptuyb licatiinotnesrio nnaatlalryee xtendtehdr ouagl hi ceinngsa greemeonnt
fuolrlp arteidaitli onTso.r equersitg hftosar l oceadli tipolne,a cseo ntaRcaty
ThibodeCaoun,t eEndtN etL LC,b yp hon(eU SA2)6 7-895-1758o re -mail
[email protected].
ISBN:9 78-1-93670945--8
LibraorfCy o ngreCsosn trNoulm ber2:0 15931368
On theC over:
LeftB:o nes cans howinmge tastaisnet sh el efatc etabualnudmi liiunma 52-yea-orld
woman.
Topr igPhitt:u itmaaryg netriecs onanicmea gi(ncgo rovniaelws )h owinagne mptsye lla
in 5a4 -yea-orldw oman.
Bottroimg Hhits:t oloegxiacm inatoifao snu rgiscpaelc imdeenr ivferdo am
thyirdoectoym,d ocumentniuncgl ebaarl loonainndng u clegarro ov(ehse matoxaynldi n
eosisnt ain).
OVERVIEW LEARNINGO BJECTIVES
TheE ndocriSneel f-AssessPmreongtr a(mE SAP™i)s a ESAP2 015 will leaalrlnotew ora ss sestsh eikrn owledogfe
self-stcuudryr icualiumme adt p hysicisaenesk iinngi tial alals pectosfe ndocrinoldoigayb,e taensd,m etabolism.
certificaotrri eocne rtificianet nidoonc rinolporgoyg,r am
directionrtse resitnae tde stianngd t rainiinnsgt rumaenntd, Uponc ompletiooftn h iesd ucatioancatli vlietayr,n ewrislb le
clinicsiiamnpslw ya ntinag s elf-assessamnedan btr oad ablteo :
revieowfe ndocrinolEoSgAyP2. 0 15i sa vailaibnbl oet hp rint • Recogniczlei nimcaanli festatoifeo nndso crianned
ando nlifnoer matIstc. o nsisotf1s 2 0b rand-nmeuwl tiple­ metaboldiics ordaenrdss eleacmto ngc urreonptt ions
choicqeu estioinnas l alr eaosf e ndocrinoldoigayb,e taensd, ford iagnosmiasn,a gemenatn,d t herapy.
metaboliTshme.r ies e xtensdiivsec ussoifoe na chc orrect Identriifsyfk a ctofroser n docriannedm etabolic
answear c,o mprehenssiyvlel abaunsd,r eferenEcSeAsP. disordaenrdsd evelospt rategfioeprsr evention.
isu pdateadn nualwliyt nhe wq uestioannsdn ews yllabus Evaluaetned ocriannedm etabolmiacn ifestatoifo ns
materials. systemdiics orders.
ESAPi sc omposeodf t wok eyc omponenttsh:ei nitial Usee xistriensgo urcpeesr taintiocn lgi nigcuaild elines
onliinnet eracmtoidvuel aen dt hep rintbeodo kU.p on andt reatmernetc ommendatifoonres n docrianned
purchaslee,a rnewrisli ln itiraelcleyia vcec estso t heo nline relatmeedt aboldiics ordteorg su iddei agnosainsd
moduleT.ou seE SAPa sa trusee lf-assesstmoeonllte, a rners treatment.
ares trongelnyc ouragteocd o mpletthee o nliinnet eractive
self-assessmmoednutlf ei rbsetf orceo ntinusienlgf -study TARGET AUDIENCE
witthh ep rintbeodo kt;h eo nlimnoed ulmea yb ea ccesseadt ESAPi sa self-stcuudryr icualiumme da tp hysicisaenesk ing
education.endocrine.org. initcieartli ficaotrri eocne rtifiicnea ntdioocnr inolporgoyg,r am
directionrtse resitnae tde stianngd t rainiinnsgt rumaenntd,
ACCREDITATIOSNT ATEMENT clinicsiiamnpslw ya ntinag s elf-assesasnmdea n btr oad
TheE ndocriSnoec ieitsya ccredibtye d revieowfe ndocrinology.
theA ccreditaCtoiuonnc fiolCr o ntinuing
MedicaEld ucatitoopn r ovicdoen tinuing STATEMENTO F INDEPENDENCE
mediceadlu catifoonpr h ysicians. Asa providoefCr M E accredibtyet dh eA ccreditation
TheE ndocriSnoec iehtays r eceived CouncfiolCr o ntinuMiendgi caEdlu catitohneE, n docrine
AccreditawtiitoChon m mendation. Sociehtays a poliocfye nsuritnhga tth ec onteanntd q uality
TheE ndocriSnoec iedteys ignattheises n durimnagt erialo ft hiesd ucatioancatli vairteby a lanceidn,d ependent,
foar maximumo f4 0.A0M A PRA objectiavneds, c ientifriicgaolrloyTu hse.s cientciofnitce nt
Catego1ryC redits™.
Physicisahnosu lcdl aiomn ltyh ec redciotm mensurawtiet h oft hiasc tivwiatsyd evelopuendd etrh es upervisoifto hne
thee xtenotft hepiarr ticipiantt ihoean c tivity. EndocriSnoec ietSye'lsf -AssessCmoemnmti ttee.
MAINTENANCE OF CERTIFICATION DISCLOSURE POLICY
TheA mericBaona rod fI nterMneadli ci(nAeB IMh)a s Thef aculctoym,m ittmeeem bersa,n ds tawfhfo a rei n
approvEeSdA P2 015a sa MedicaKln owledMgaei ntenance posititoocn o ntrtohlec onteonftt his acatrievr ietqyu ired
ofC ertifica(tMiOoCn)a ctiv(iite"y,M OCP ar2t" )P.h ysicians tod isclotsote h eE ndocriSnoec ieatnyd t ol earnearnsy
enrollienAd B IMM OC whos uccessfcuolmlpyl etthee relevafinnta ncriealla tionsohfit ph(eis n)d iviodrus aplo use/
120-questpiroong rawmi tah m inimupma ssinsgc oroef partntehra hta veo ccurrweidt htihne l as1t2 m onthwsi th
70% wilrle cei4v0ep ointtso wardtsh eM edicaKln owledge anyc ommerciianlt ereswth(oss)ep roducotrss ervices
requiremTehnitms.o dulwei lall sfou lfAiBlIlM 'Psa tieSnatf ety arer elatteotd h eC ME contenFti.n ancriealla tionasrhei ps
certificarteiqouni rement. definbeydr emuneratiinao nny a mounftr omt hec ommercial
Thiasc tiviisat nyA ccredited interesitnt( hsef) o rmo fg rantrse;s earscuhp porcto;n sulting
Self-AssessPmreongtr am feess;a laroyw;n ershiinpt er(eesgts, t ocksst,o cokp tions,
(Secti3o)an s d efinbeydt he oro wnershiinpt ereexsctl udidnigv ersimfuiteudaf lu nds);
uT ShoCcoao 0nt6 �SC>d�odanlaldo3yllon n nb d olldlltdMnWu b'-' lDbbD-Ilosllmiom M aintenanocfCe e rtificationh onoraorrio at hepra ymentfso pra rticipiants ipoena kers'
PrograomfT heR oyaClo llege bureauasd,v isobroya rdosr,b oardosf d irectoorro st;h er
ofP hysiciaanndsS urgeonosfC anadaa,n da pprovbeyd financbieanle fiTthse.i nteonftt hidsi sclosiusnr oet t o
TheC anadiaSno cieotfyE ndocrinoalnodgM ye taboliosnm preveCnMtE plannewrist rhe levfaintn ancriealla tionships
01/03/20P1r5o.g raamc creditaetxipoinr0 e3s/ 201Y8o.u m ay fromp lannionrgd elivercionngt enbtu,tr athteorp rovide
claiam m aximumo f1 4h ourfso ErS AP2 015. learnewristi hn formattihoaantl lowtsh emt om aket heoiwrn
3
judgmenotfsw hethetrh esfei nancriealla tionmsahyih pasv e DRUGSA NDD OSAGES:
influentcheeed d ucatioancatli vwiittyrh e gartdoe xposition Whenp rescrimbeidnigc atiotnhsep ,h ysiciisaa nd vistedo
orc onclusiTohneE. n docriSnoec iehtays r eviewaeldl chectkh ep roduicntf ormatsihoenea tc companyienagc h
disclosuarnedrs e solvoermd a nageadl ild enticfoinefdl icts drugt ov ericfoyn ditioofnu ss ea ndt oi dentainfyyc hanges
ofi ntereassat p,p licable. ind rugd osagsec heduolrec ontraindications.
Thef aculrteyp orttehdef ollowrienlge vafnitn ancial
relationsdhuirpi(ntsgh) ec ontednetv elopmepnrto cesfso r POLICYO N UNLABELEDO/FF-LABEULS E
thiasc tivSihteyh:z ad BasariMaD,, isa consultant forT heE ndocriSnoec iehtays d etermintehdad ti sclosoufr e
5.
ElLii lKlayt.h ryMnc CrystDaalh irM,D , iso nt hea dvisory unlabeled/ofofri- nlvaebsetli gautsieoo nfca olm mercial
boarfdo Arl exioTnho.m asW .D onnerM,D , isa studsyi te producti(sis n)f ormaftoiarv ued iencaensd t herefore
princiipnlvee stigfaotrNo orv oN ordisJka.m esW . Findling, requirtehsii sn formattiobo end isclosteotd h el earners
MD, isa ni nvestigator/cfoonCrs ourlcteapTntht e rapeutics att heb eginnionftg h ep resentatUisoenso. fs pecific
andN ovartPiasm.e la FredaM,D , isa ni nvestigfaotro r therapeuatgiecnt dse,v iceasn,do theprr oducdtiss cussed
U.
NovartainsdI psesni,t osn t hea dvisobroya rfdo Prf izaenrd, int hiesd ucatioancatli vmiatyyn otb et hes amea st hose
isa conternetv iewfeorrU p ToDateD.u keU niversity receiinvdeisc aitnep dr odulcatb elaipnpgr ovbeydt heF ooda ndD rug
fundfsr omM ercka ndA myli(nn owB MS/AstraZenfeocra ) Administr(aFtDiAoT)nh. e E ndocriSnoec ierteyq uirtehsa t
researpcehr formbeydJ ennifGerre enM,D . Thesfeu nds anyd iscussioofsn usc h" off-laubseebl e"b asedo ns cientific
suppoart portioofnh ers alarDyr..G r eehna sa lsroe ceived researtchha cto nfortmosg eneraalclcye ptsetda ndards
honorafrrioamM erckf osre rviansga consulthaonnto,r aria ofe xperimendetsailg dna,t ac ollectainodnd ,a taa nalysis.
fromB ioScientfioferid ciat oraicatli viatnideh sa,sr eceived Beforree commendionrpg r escriabniynt gh erapeuagteinct
publicastuipopno srte rvicferso mB oehrinlgnegre lheim. ord eviclee,a rnesrhso ulrde vietwh ec ompleptree scribing
SuzanneM .J and eB eurM,D , iso nt hed atsaa fety informatiinocnl,u diinndgi caticoonnst,r aindications,
monitorbionagr fdo Kr KP PharmaI,n ca,n dT issueGeInnec,. warningpsr,e cautiaonndsa ,d verseev ents.
Shei sa consultfaonKrtK P Pharmaan ds anofi-aveSnhte is.
isa lsaon i nvestigfaotErol rLi i lAldyr.i aVn. V ellaM,D ,i sa PRIVACYA ND CONFIDENITALITYS TATEMENT
consultfaonsrta nofi-avaenndtG iesn enteacnhd r eceives TheE ndocriSnoec iewtiyl rle corlde arnepre'rss onal
granstu ppofrrto mN ovartainsdB ioKiCeorr.r inWee ltM,D , informataisp orno vidoendC ME evaluatitooan lsl ow for
isa writfeorrU pToDataen da consultfaonArts trZae neca issuanacned t rackionfCg M E certificTahteEe nsd.o crine
andT akeda. Sociemtayy a lstor acakg gregartees ponsteoqs u estioinns
Thef ollowcionmgm ittmeeem berrse portneodr elevant activiatnidee sv aluatiaonndus s et hesdea tat oi nfortmh e
financriealla tionsKhriipsst:iB eone laertM,D ; MariaL . ongoinegv aluatainodni mprovemeonfit t CsM E program.
Collazo-CiaMvDe;l All,a nC .C alkiMnD,; MarieF reeMlB,, Noi ndivipdeuralf ormadnacteoa r a nyo thepre rsonal
ChB,P hD;S hubhadJaa gasiMaD,, MMHC; Jacqueline informatcioolnl ecftreodme valuatiwoinlbsle s harewdi th
JonklaaMsD,, PhD;a ndL isa TannockM,D . thirpda rties.
R.
Them ediceadli tfoortr h ipsr ograAmb,b ieL .Y oungM,S ,
CGC,E LS(D),r eportneodr elevafnitn ancriealla tionships.A CKNOWLEDGMENTO F COMMERCAILS UPPORT
TheE ndocrine Ssotcaiaefstfsy o ciawtietdth h e Thiasc tiviisst uyp portebdy a ne ducatiognraalnf tr om
developmeonfct o ntefnottr h iasc tivrietpyo rtneodr elevant AstraZeneLcPa,M, e rck Co.I,n ca.n,d N ovoN ordiIsnkc .
&
financriealla tionships. Additiosnuaplp orteirn formatwihoinc,wh a sn ota vailable
att het imoef p rintimnagy,b ef ounidn t heo nlimnoed ulaet
DISCLAIMERS educat.ieonnd ocroirnge..
Thei nformatpiroens entientd h iasc tivrietpyr esetnhtes
opinioofnt hef aculatnydi sn otn ecessatrhieloy f ficial AMA PRA CATEGORY 1C REDfT(CME) INFORMATION
positiooftn h eE ndocriSnoec iety. Tor eceiav mea ximumo f4 0.0 AMPAR A
Catego1ryC redits,
participmaunsttcs o mpletthee o nliinnet eracmtoidvuel e
USEO FP ROFESSIOJNUADLG MENT: anda ctiveivtayl uatlioocna taetde ducation.endocrine.
Thee ducatiocnoanlt einntt hisse lf-assesstmeesrntet l ates orgP.a rticipamnutssta chieav mei nimusmc oroef 7 0% to
tob asipcr incipolfde isa gnosainsdt heraapnyd d oes claiCmM E crediAtf.t eirn iticaolmlpyl ettihnegm odulei,f
nots ubstitfuotiren divipdautaile ansts essmebnats edo n participdaonn tosta chieav mei nimusmc oroef 7 0%,t hey
theh ealtchar pe rovideerx'asm inatoifot nh ep atieanntd havet heo ptiotnoc hangteh eainrs werasn dm akea dditional
consideraotfli aobno ratdoartya aontdh efra ctournsi que attempttosa chieav pea ssisncgo reL.e arnearlss hoa vet he
tot hep atieSntta.n daridnms e dicicnhea ngaes n ewd ata optiotnoc leaarla ln swerasn ds tarovte r.
becomea vailable.
4 ESAP2 015
METHOD OF PARTICIPATION
Thiesn durimnagt eriiaspl r esentoendl ianned i np rifnotr mat.
Thee stimatteidm teo c ompletthei asc tiviintcyl,u ding
revieowfm ateriias4l 0,h oursP.a rticipamnutssta chieav e
minimusmc oroef 7 0% toc laiCmM E credaintd M OC points.
Afteirn iticaolmlpyl ettihnegm odule(isfp) a,r ticipdaon ts
nota chieav mei nimusmc oroef 7 0%,t hey htahveeo ption
toc hangteh eainrs werasn dm akea dditioantatle mpttos
achieav ep assisncg orPea.r ticipaalnstos haveo pttihoet no
cleaarla ln swerasn ds tarotv er.
SYSTEM REQUIREMENTS
Toc ompletthei asc tivpiatrtyi,c ipantsh amvueas ctc estsoa
computoerrm obildee vicwei tahn I ntercnoentn ectainodnu se
a majoWre b browsesru,c ha sI nterEnxeptl or0e+r, F 1i refox
32+S,a faroirG, o oglCeh rome3 7+I.n a dditicoono,k iaensd
Javascrmiupsttb ee nableidnt heb rowseorp'tsi ons.
LASTR EVIEW DATJEa:n uar2y0 15
ACTIVITRYE LEASED ATE:M arch1 ,2 015
ACTIVITEYX PIRATIODNA TE:Ma rch3 0,2 018( date
aftewrh icthh iesn durimnagt eriiasnl o l ongecre rtiffioerd
AMA PRA andA BIMM edicaKln owledge
Catego1ryC redits
MOC points)
Forq uestioanbso ucto nteonrto btainCiMnEg credoirtM OC
pointpsl,e asceo ntatchte E ndocriSnoec ieattye ducation@
endocrine.org.
5
LaboratRoerfye reRnacneg es
Referenrcaen ges vary laamboonrga toTrhieel si.s treedf erence rsahnoguelbsde u sed whiennt erpreltaibnogr atvoarlyu epsr esentiend
ESAP™.C onventiounnailta sr el istfeidrw sitt Shl u nitisnp arentheses.
LipiVda lues
Hig-hdensiltiyp opro(HtDeLi)cn h olesterol Thyrdo-sitimula-t-i-n-g- -,;-1-2-0-%o fb asailm munoglobaucltiinv ity
Optim-a-l------------------------------>--6-0m- g/dL(> 1 .5m5m oi/L) immunoglobulins
Norma--l------------------------4-0--6-0-m -g/d(L1 .-014.5m5m oi/L) Thyroperox(idTOaP)sa en tibo-d-i-e-s---<-2-.-I0-U -/-m(L< 2.k0i U/L)
Low---------------------------------<--4--0m-- g-/d(L< 1.m0m4o i/L) T4 ( fr-e-e-)------------0-.--8-1-.-8n- g-/-d(-L01- . -3--20-3-.-1p7m oi/L)
Low-densiltiyp opro(tLeDiLcn)h olesterol T (tot-a-l-)---------------5--.---51--2-.-�5g /d(L9 4.-20123.6n8m oi/L)
4
Optim-a-l---------------------------<--10-- 0-m -g/d{L< 2.m5m9o i/L) FreeT4 i nde-x- ---------------------------4--1-2- --------------------------
Low----------------------------1--0 0-129m g/dL( 2.-539.3m4m oi/L) T3( fr-e-e-)-------------------------2-.--34-.-2p g/m(L3 .-563.4p5m oi/L)
Border-lhiginhe --------1-3-0--1-5-9m- g-/-d-(L3 .-347. 1m2m oi!L) T3( tol)t-a------------------------7-0--2-0-0n- g-/-d(L1 .-038.0n8m oi/L)
Hig-h--------------------1--6--0--1--8-9-m g/d(L4 .-144.9m0m oi/L) T u3p takree,s -i-n----------------------------------2---5-%- ---3-8-%- ----
Veryh ig-h- ------------------;o,-1- -9--0-m -g-/-d-(L-;o, -4-.m9m2o i/L) Radioactiiovdeiu npet a-k-e3-%-16% (6h ours1)5;%- 30% (24h ours)
Non-HDLc holesterol
Optimla------------------------------<--1--3-0m g/d(L< 3.m3m7o i/L) EndocriVnael ues
Bordeirn-lehig-h- --------1-3-0-1-5-9-m -g-/-d(L3 .-347.1m2m oi/L) Serum
Hig-h---------------------------------;o,--2--4-0m g/d(L;o, 6.m2m2o i/L) Aldoste-r-o-n-e-----------1--2-1-n -g-/-d-(L-2 -77--.5- 8--2p-.m5o i/L)
Totaclh olesterol Alkalpihnoes phat-a-s-e------------5-0--1-2-0-U /L( 0.-824.0�0k at!L)
Optim-a-l----------------------------<-2-0-0-m -g/dL( <5.m1m8o i/L) Androstene6d5i-2o1n0en g/d(L2 .-277.3n3m oi/{La)d umlatl e8)0;-2 40
Border-lhiinge-h- --------2-0-0-2-3-9-m -g-/-dL( 5.-168.1m9m oi/L) ngld(L27 .9- 8.3n8m oi/(La)d ufletm ale)
Hig-h-----------------------------------;o,-2-4-0m g/dL( ;o,6.m2m2o i/L) Calciitn-o -n<16p g/mL (<p4m.o6i7! (Lb)a samall,e <)8;p g/m(L< 2.34
Triglycerides pmoi/(Lb)a sfaelm,a l,;e1)3;0p g/mL( 37.p9m6o i/{Lp)e ak
Optim-a-l---------------------------<--1--5-0m- g/dL( <3.m8m8o i/L) calciiunmf usimoanl,e,; )9;0 p g/m(L2 6.p2m8o i/(Lp)e ak
Border-lhiinge-h- --------1-5-0-1-9-9-m -g-/-d{L3 .-858.1m5m oi/L) calciiunmf usifoenm,a le)
Hig-h------------------------2-0-0--4-9-9m g/d{L5 .-1182.9m2m oi/L) Corticotro(pACiTnH) -----------1-0-6-0-p -g-/-m-(L-2 -.-123.p2m oi/L)
Veryhi gh- ---------------------;o,--5--0--0-m- -g-/d(L;o, 12.m9m5o i/L) Cortiso(l8A M)-------------5--2-5-� -g-/-d-(L-1 -3.-79--6 -89.n7m oi/L)
Lipopro(tae-)i-n- -------------,;-3-0-m -g-/-d-(L,;- 1-.-0-�7-m -o-i-/-L) Cortiso(l4P M)--------------2--1-4-� -g-/-d(-L5- 5--.-32-8-6-.n2m oi/L)
ApolipoprBo -t-e-i-n- ----------5-0-1-1-0-m -g-/-d-L(- 0-.-1-5.--1g /L) C-pepti-d-e- ------------0-.--94-.-3n- g-/-m-(L-0 -.--3-10-.-4n2m oi/L)
C-reactpirvoet e-i-n---------0-.--83-.-1m- g-/-L(- 7-.-6229.5n2m oi/L)
HematologViacl ues Cros-lsinkNe-dt elopep-t-i-d-e- -----5-.--42-4-.-n2-M - B-C-E (male);
Erythrosceydtiem entartait-oe-n - ---------------------0--2-0-m -m-/-h- oft yp1e c ollagen 6.-219.n0M BCE (female)
Haptoglo-b-i-n- -----------3-0-2-0--0m- g-/-d-(L-3 -0--20-0-00m g/L) Dehydroepiandrossutlefra(otDHneEe A -S)
Hematoc-r-i-t-4-1-% ---50% (0.-401.51()m al3e5)%;- 45% (0.-305.45) Female Male
(female)A ge1 8-29y ears4 4-332� g/dL 89-457� g/dL
HemoglobAin- ---------------4-.-7--%-5-.-8-(%-0 -.-0--04-.7-0 -5-8) (1.-199.0�0m oi/L) (2.-4112.3�8m oi/L)
10
Hemoglio-nb-----------------------1-4-.--10-7-.-g5-/ -d-L- --A-g-e3- 0--3-9-y -e-a-r-s-3 -1-228� g/dL 65-334� g/dL
Meanc orpusc-u-l-a-r- -----------8-0--1-0 -0-� -m3-( -8--01-0 -0-f -L-)- - (0.-864.7�8m oi/L) (1.-796.0�5m oi/L)
volum(eM CV) Age4 0-49y ears1 8-244I Jg/dL 48-244� g/dL
Platecloeutn -t-----------15-0--4-5-0-x -1-03-/ -�-L( 15-0450x 10/9L ) (0.-469.6�1m oi/L) (1.-360.6�1m oi/L)
Prote(itno t-a-l-)- --------------6-.--3-7-.-9g- /-d-(L-6 --37-9-g -/-L-)- -A-ge5 0-59y ears1 5-200� g/dL 35-179� g/dL
Reticuloccoyutn-et- --0-.-5--%-1.5%o fr edb loocde l(l0s. 0-00.5015) (0.-451.4�2m oi!L) (0.-945.8�5m oi/L)
Whitbel oocde lclo un-t-------4-5-0--01-1-,-000/(�4L.-1 51.x0 1 0 9/ L) Age;o, 60y ears 15-157� g/dL 25-131� g/dL
(0.-441.2�5m oi/L) (0.-638.5�5m oi/L)
ThyroiVda lues 1,2-D5ihydroxyviD3t- a-m-i-n- --1-6--6-5-p -g-/m(L4 1-.1669p moi/L)
Thyroglloib-nu- -3--4-2n g/m(L-3 42� g/L{)a ftseurr gearnydr adioactivEes trad-i-o-l- -----------1-- ---04--0-p g/mL( 367-.1 46.p8m oi/(Lm)a le);
ioditrneea tmen<t1:.n 0g /m[L< 1.�0g /L]) 15-350p g/m(L5 5-.11284.p8m oi/(Lp)r emenopafuesmaall) e;*
Thyrogloabnutliibno d-i-e-s- --------,;-4-.-0IU- /-m-L-(,; -4-.-0k- iU/L) <10p g/m(L< 36p.m7o i/(Lp)o stmenopfaeumsaall*e l)e vvealrsy
Thyrotropi(nT HS)- --------------------0-.--5-5-.-0m- i-U-/-L- -----w-i-d-e-tl-hy-r oumgehn strcuyacll e
6 ESAP 2015
Estro-n--e--1- --060p g/m(l3 7-.1046.p8m oi/(Lm)a le1)7-2;0 0p g/ml Age6 1-65y 72-207n g/ml 72-207n g/ml
62.-7939.p6m oi/(Lp)r emenopafuesmaall 7e-)4;0 (9.-247.n1m oi/L)( 9.-247.n1m oi/L)
pg/ml( 25-.1947.p9m oi/(Lp)o stmenopfaeumsaalle ) Age6 6-70y 67-195n g/ml 67-195n g/ml
a-Fetopr-o-t-e-i-n- ---------------<-6-n -g-/-m-(l-< -6�- g-/-L-)- ------- {8.-285.n5m oi/L)( 8.-285.n5m oi/L)
Foll-isctliemula-t-i-n--g-- --------------------1-.--01-3-.-m0-i -U-/-m-L- Age7 1-75y 62-184n g/ml 62-184n g/ml
hormon(eF HS) (1.-103.I0U /(Lm)a le<)3;.m 0i U/m(L< 3.I0U /L) (8.-214.n1m oi/L)( 8-.214.n1m oi/L)
(preputbyfe,er mal2e.)-01;2 .m0i U/m{L2.-102.I0U /L) Age7 6-80y 57-172n g/ml 57-172n g/ml
(follicular4,. -03f6e.mm0ai lUe/)m;(L 4 .-306.J0U /L) (7.-252.n5m oi/L)( 7.-252.n5m oi/L)
(midcyfcelmea,l 1e.)-0;9 .0m iU/m(L1 -.90.0I U/L) >Age8 0y 53-162n g/ml 53-162n g/ml
{lutefaelm,a le) (6.291-.n2m oi/L)( 6.-291.n2m oi/L)
Frefea tatcyi d--s-----------1-0-.--16-8-.m-0g- /-ld- (-0.-04.7n moi/L) lnsulignrloiwktfeha ctboirn dipnrgo te3i -n- ---------------2.-54.m8g /L
Gastr-i-n- ----------------------------------------<10 0p g/m(l< 010 n g/L) Insul-i-n- ----------------------1-.--41-4-.-�0-I -U/m(l9 7.-9 7.p2m oi/L)
Growthho rmon(GeH )- ---0-.-0--01.9n7g /m(l0 .-001.9�7g /L()m ale);I sl-ectelaln tiboadsys a-y-----0-J -u-v-enile DiFaobuentdeastu inoint s
0.0-31.6n1g /m(l0 .-031.6�1g /L()f emale)L uteinihzoirnmgo n(eLH )- -----------1-.--09-.-0m- i-U/m(L1 -.90.0I U/L)
Homocyste-i-n-e---------------,;-1-.7- 6-m -g-/-L(- :s-1-�3-m -o-i-/-L-) (mal<e1).;m0 i U/m(L1 .IU0/ L()p reputyb,fe ermal1e.)-01;8 .m0i U/
�-Humanc horiognoinca dotr-o-<p3i.nm0i U/m(L< 3.I0U /nLo)n pregnant ml (1-.108.I0U /(Lf)o llifceumlaalr2e,0) .;0 -8m0i.U0/ m(L2 0.0-80.0
�-hCG) femal>e2;5m iU/m(L> 2I5U /Li)n dicaatp eoss itive IU/L()m idcycfleem,a l0e.)-5;1 8.m0i U/m(L0 .-158.I0U /L()l uteal,
pregnantceys t female)
�-yHdroxybut-y-r-a-t-e- --------<-3-.-m0-g -/-d-l(- <-3-0-�0-m -o-i/L) Metanephr{ipnleass fmraa ctionated)
17- Hydroxypregne-n-o-l-o-n-e- 2-9--1-8-9n- g/d(l0 .-857. 6n9m oi/L) Metaneph-r-i-n-e-- ----------------<-5-7p- g-/-m-(l-< -2-8p-9m- o-i-/L)
17a-Hydroxyproges-t-e<-r2o2n0ne g /d(l< 6.n6m7o i/(La)d umlatl e); Normetanienpe-h-r---------------<--1--4-8p- g-/-m-(l-< -8-0p-8m oi/L)
<80n g/d(l< 2.n4m2o i/(Lf)o llifceumlaalr<e,2) 8;5 n g/dl 75-go ragll ucose totleesr(taf nacset- i6n0-1g0)0m g/d(l3 .-53.6m moi/L)
{<8.n6m4o i/(Ll)u tfeeamla,l <e5)1;n g/d(l< 1.n5m5o i/L) Bloogdl ucovsael u-e-s- ----------------<200m g/dl( <11m.m1o i/L)
(postmenopafuesmaall,e ) (1h our<)1;4 0m g/d(l7 .m8m oi/(L2)h ourB)e.t wee1n4 0-200
25-HydroxyvitDa -m-i-n- --------<--1-0- ng/m(l< 25n.m0o i/(Ls)e vere mg/d(l7 .-181.m1m oi/iLs)c onsideirmepda irgeldu cotsoel erance
deficie1n0c-2y4)n ;g /m(l2 5-.509.n9m oi/mLi)l tdo m oderate orp rediabegtreesa;tt ehra 2n0 0m g/dl( 11.m1m oi/iLs)a s igonf
deficie2n5c-y8)0n; g /m(l6 2-.1499.n7m oi/(Lo)p timluemv els); diabetmeesl litus
>80 ng/(m>l1 99n.m7o i/(Lt)o xipcoistsyi ble) 50-g oragll ucotsoel eratnecs-et-- -<140m g/dl( <7.m8m oi/(L1)h our)
lnhibBi -n- ---------------------------------1-5-300p g/m(l1 -5300n g/L) fogre statidoinaable tes
lnsulignrloiwktfeha ct1o Ir(G F-1) 10 0-g oragll ucotsoel era-n-c-e---<-9-5 mg/dl m(m<o5i./3{L f)a sting);
Female Male tesfto gre statidoinaable tes <180m g/d(l< 01. 0m moi/(L1)h our);
Age1 8y 162-54n1g /ml 170-640n g/ml <155 mg/dl (<8.6( 2h momuori)/;L )
(21-.720.n9m oi/L()2 2-.833.n8m oi/L) <140m g/dl(< 7.m8m oi/(L3)h our)
Age1 9y 138-442n g/ml 147-52n7g /ml Osteoca-l-c-i-n- ---------------9--.---0-4-2-.n-0g- /-m(l7 .-402.�0g /L)
{18-.517.n9m oi/L)19 .-639.n0m oi/L) Parathyhroorimdo n(PeT H)( int-a-c-t-)--1- --06-5-p -g-/m(l01 - 65n g/L)
Age2 0y 122-384n g/ml 132-457n g/ml Parathyhroorimdo ne-relpartoetde{ PiTnHr p--)14-27p g/m(L1 -427n g/L)
(16-.500.n3m oi/L()1 7-.539.n9m oi/L) Progeste-r-o-n-e------------------:s-1-.-n2-g -/-m-l(- :s-3-.-8- ---------
Age2 1-25y 116-341n g/ml 116-341n g/ml nmoi/(Lm)a le:s)1;.n 0g /m(l:s 3.n2m oi/(Lf)o llifceumlaalr2e-,2) 0;
(15-.4247. n moi/L)( 15-.4247. n moi/L) ng/m(l6 -.653.n6m oi/{Ll)u tfeeamla,l ,;e1).;1n g/m(l:s 3.n5m oi/L)
Age2 6-30y 117-321n g/ml 117-321n g/ml (postmenopafuesmaall,>e1 )0;n g/m(l> 31n.m8o i/(Le)v idence
(15-.432.n1m oi/L()1 5-.432.n1m oi/L) ofo vulataodreyq uacy)
Age3 1-35y 113-297n g/ml 113-297n g/ml Proinsu-l--i-n- ---------2-6-.--15-7-6-.p-4g- /-m-(l-3 -.-200.p0m oi/L)
(14-.388.n9m oi/L)( 14-.388.n9m oi/L) Prolac-t-i4--n2 3n g/m(l0 .-117.0n0m oi/(Lm)a l4e-)3;0n g/m(l0 .-117.30
Age3 6-40y 106-277n g/ml 10 6-277n g/ml nmoi/{Lf)e male)
(13-.396.n3m oi/L)( 13-.396.n3m oi/L) Prost-astpeeciafnitci g-e-n----------------------<2.n0g /ml{ <2.�0g /L)
Age4 1-45y 98-261n g/ml 98-261n g/ml (,;4y0e ars<)2;.n 8g /m(l< 2.�8g /L(),; 5y0e ars<)3;.n 8g /m(l< 3.8
(12-.384.n2m oi/L)( 12-.384.n2m oi/L) Jg./JL():s 6y0e ars<)5;.n 3g /m(l <5.�3g /L():s 7y0e ars<)7;.n 0g /ml
Age4 6-50y 91-246n g/ml 91-246n g/ml (<7.�0g /L():s 7y9e ars<)7;.n 2g /m(l< 7.�2g /L()<! 8y0e ars)
(11-.392.n2m oi/L)( 11-.392.n2m oi/L) Renianc tivity, Npal+ra espmlae,at meb,u lat-o-r-y-0 -.--64.3n g/mUh
Age5 1-55y 84-233n g/ml 84-233n g/ml Renind,i reccotn centr-a-t-i-o-n---3-0--4-0p- g-/-m-(l0 .-17.0p moi/L)
(11-.300.n5m oi/L()1 1-.300.n5m oi/L) Sexh ormone-bin-d-i-n-g- -1-.--1-6-.-7� g/m(l01 - 60n moi/(Lm)a le);
Age5 6-60y 78-220n g/ml 78-220n g/ml globulin 2.-214.�6g /m(l2 -0130n moi/L)
(10-.228.n8m oi/L() 01. -228.n8m oi/L) (female)
7
a-Subunoiftp ituigtlayrcyo prohtoerimno n-e<s1.n2g /mL( <1.IJ2g /L) Aldosrotnee----------------3---2-0I gJ/2h4 ( 8-.535.n4m ol/(ds)h oubled
Tetsoster(obnieo aavbalie-l)-0 -.-84.0n g/d(L0 .-003.1n4m oi/(L2)-05 0 <12IJ g/2h4 [ <33n.m2o l/wdi]t ohr al
years, foenmo arlaeels trog0e.n8)-;1 0.0 (n0g./-00d3.L3 n5m oi/L) sodiulmo ading-confwiirt2mh4e -hdo ur
(2-050y earfse,m alneo to no raels trog8e3n.)-20;5 7.n0g /d(L2 .-88 urirnya sodiu>m2 00m Eq)
8.92n moi/(Lm)a l2e0 -29 years7)2;.- 2035.n0g /d(L2 .-580.15 Calci-u-m- ---------------------0--0--3-0-0m- g1/2h4 (0.-75. 5m mol/d)
nmoi/(Lm)a l3e0- 39y ears6)1;. 201-3.n0g /d(L2 .-172.3n9m oi/L) Catechoilnafemr actionation
(mal4e0- 49y ears5)0;.-1 090.n0g /d(L1 .-764.5n9m oi/(Lm)a l5e0- Dopamin-e------------------------<---7-0-0I- Jg/h2 (4< 456n7m ol/d)
59y ears4)0;.-1 068.n0g /d(L1 .-359.8n3m oi/(Lm)a le- 669y0 ears) Epinephr-i-n--e--- ----------------------<-3-5I- gJ/2h4 ( <911 n mol/d)
Testosrotnee( fre-e-)- -----9---30-n -g-/-d-(L-0 .-311.0n4m oi/(Lm)a le); Norepinep-h-r-i-n-e- -------<-1-7-0I- J-g-/-h2- <4-1( -0 0-5-n mol/d)
0.-31.n9g /d(L0 .-00.10n7m oVL()f emale)C orti-s--o-l----------------------------4---5-0I- J-g/h2 (41 -1138n moi/L)
Testoster(otnoet- a-l-)---3-0-0-9-0-0n g/d(L01 . -431.n2m oi/(Lm)a le);D examethassounpep ress-i-o-n-----<-10- J-Ig-/-2-h4 ( <27n.m6o i/L)
8-60n g/d(L0 .-23.1n moi/(Lf)e male) tes(tl o-wdos2e d:a y2, m g
dailuyr)i,n afrryec eo rtisol
Chemitsry Values Creati-n-i-n-e- -------1--2- -g-/-2h-4 -( -1--52-0m- g-/kg/h2,4f emale;
Alanianmei notrans-f-e-r-a-s-e-------1-- --04-0-U /L( 0.-107. 617J kat/L) 20-25m g/kg/h2,4m ale)
Album-i-n- ------------------------------3-.--5-5-.-g0-/ -d-(L-3 -550g /L) Glomeruflialrt rraatti-eo-n- --------->-6-0-m -U-m-i-np- e-r-1 -.-7m32
Amyla-s-e--------------------2--6---1-0 -2U- /-L-( -0-.--41-3.710J kat/L5)- Hydroxyinadcoelteai cci -d- ------0--6- m-g-/-2-h4 ( -031.I4mJ ol/d)
Aspartaamtien otrans-f-e-r-a-s-e--2-0--4-8-U -/-L(- 0.-303.810J kat!L1)7 -Ketoste-r-o-i-d-s-6 -.--02-1-.m0g /2h4 ( 20-.782.1J9m ol/(dm)a le);
Bicarbo-n-a-t--e---------------------2-1--2-8m- E-q-/L( 2-128m moi/L) 4.-017.m0g /2h4 ( 13-.599.I0mJ ol/(df)e male)
Bilir(utboitn-a -l-)- ----------.-3--1-.-2m- g-/-d-L(- 5-.-2-10-.0I5J moi/L)M etanephfrrianec tionation
Bloogda ses Metaneph-r-i-n-e-- -------------------<-4-00I Jg/h2 (4< 202n8m ol/d)
Po2,a rterbilaolo- d- ---------8-0-1-0-0-m -m- H-g- (-01. -613.k3P a) Normetanep-h-r-i-n-e- ------<-9-0-0IJ- g-/-2-h4- ( -<-4-91n4m olld)
Pco2,a rterbilaolo- d-----------3-5--4-5-m -m- H-g- (-4-7.--6 .0kP a) Totmaelt aneph-r-i-n-e- -----<-1-0 -0-0I- J-g-/-h2- <4-(5 260n mol/d)
BloopdH -------------------------------------------7-.-3--75-.-4-5- --A-l-b-u-m--i-n- ------------3-0--3-0-0I- gJ/mgc rea(t3 .-343.I9J g/mcorle at)
Calci-u-m--------------------------8-.--21-0-.m2g /dL( 2.-21.6m moi/L) Osmolal-i-t-y- ----------------30-0---8-m0-0Os mlk(g3 0-8000m mollkg)
Calciu(mio ni-z-e-d-)- ------4-.-6--50-.-0-m8-g -/-d-L( 1.-12.3m moi/L) Oxala-t-e---------------------------<-4-0- -m-g-/-h2- (4-< 45m6m ol/d)
Carbodni odxei------------------2--2-2-8-m -E-q-/-L(- 2--228m moi/L) Phospho-r-u-s-------------<--0--.--19-.-3g- /-2h4 ( 29-.412.m0m ol/d)
CD4 c elclo un-t- -------------5-0-0-1-4-0-0I-L/J- (-0-.--15-.-4x- 10 9/ L) Potassi-u-m- ----------------------1--7--7-7-m Eq/2h4 ( 1-77 7m mol/d)
Chlor-i-d-e-----------------9--6--1-0-6m- E-q-/-L(- 9--6-10- 6m moi/L) Sodiu-m------------------------4-0--2-1-7-m -Eq/2h4 ( 4-0217m mol/d)
Creatiknien a-s-e------------5-0--2-0-0U- /-L-( -0-.--83-4.-3-14J kat!LU)r iacc i-d- --------------------------<--8--0--0m- g-/24h (<4.m7m ol/d)
Creati-n-i-n-e----------0-.--6-1-.-2m- g-/-d-L(- 5-3--.1-00 -6.I1Jm oi/L)
Ferr-i-t-i-n--------------------------1-5--200n g/m(L3 37-.4 49.p4m oi/L) Saliva
Gluco-s-e---------------------------7-0--1-1-0m g/dL( 3.-69.1m moi/L) Corti(ssoall i)v,ma irdyni-g-h-t-------<-0-.-1I-3J- g-/-(d-<L-3 .n6m oi/L)
y-Giutamyltran-s-f-e-r-a-s-e- ----2--3-0-U -/-L(- 0-.--00-3.-5I0kJ at!L)
Iron- ----------------------------5-0--150I Jg/(d9L. 206-.I8mJ oi/(Lm)a le);S emen
35-1451-Jg/(d6L. 236 .I0Jm oi/(Lf)e male)S emena naly-s-i-s--------------->-20m illsipoenr m/m>L5;0 %m otility
Lactadteeh ydrogen-a-s-e- ------1-0 -0--2-0-0U- /-L(- 1-7.-3 .31 Jkat!L)
Lactaicci -d----------------5--.--42-0-.-m7-g -/-d-L(-0 -.-06.9m moi/L)
Lipa-s-e-- ---------------------------------1- -07-3U /L( 0.-117. 212J kat!L) Abbreviations
Magnesi-u-m-------------------------1--.-52.3m g/dL( 0.-06.9m moi/L)
Osmolal-i--t--y- --------------2--75-295m Osm/k(g2 7-2595m mol/kg) ACTH- ----------------------------------c-o-r-t-iro-cp-oi-tn- ---------------
Phospho-r-u-s--------------2--.--34-.-7m- g-/--d-L(- 0--.17.5m moi/L) ACE inhib-i-t-o-r- ----a-n-g-i-o-t-e--cn-os-nivnerteinnzgy mineh ibitor
Potassi-u-m- ----------------3-.--55-.-0m- E--q-/-L(- 3-.-55.0m moi/L) BM 1-----------------------b-o-d-ym- a-s-si -n-de-x- ----------------------
Prothromtbmiie-n- -------------------------------------------8-.--31-0.s8 CNS- ----------------------------------------c--e--n-t-rnaelr vosuyss tem
Serumu renai tro-g--e-n- ------------8--2-3-m -g-/dL( 2-.89.2m moi/L) CT ---------------------------------------c-o-m-p-u-t-et-do- m-ography
Sodiu-m---------------1-3-6--1-4-2m- E-q-/-L(- 1-3--16-4-2-m moi/L) DHE A- ----------------------------------d--e--h--y-rd-o-eapnidr osterone
Transfesrartiunr a-t-i-o---n-- --------------------------------1-4-%--50% DHEA-S -----------------------------d--e-h-ydroeproisatnedrosnuel fate
TroponiI-n - ----------------------------------<-0-.-m6-g /mL( <0.Ig6J/ L) DNA- ------------------------------------------d--e-o-xi-ybronuclaeciicd
Trypta-s-e-----------------------------------<--1-1.n5g /mL(< 11I.J5g /L) DXA ----------------------------d--u-a-e-ln-e-r-gx-yr aya bsorptiroym et
Uriacc i-d- -----------------3-.--5-7-.-0m- g-/-dL( 208-4.126.IJ4m oi/L)F NAB- -----------------------------f-i-n-n-ee-e-d-la-es- p-irabtiioopns y
FSH - ------------------------------f-o-ii-cl--l s-et-mi- lu-a -nt-gi-h -ormone
Urine GH -------------------------------------------------g--r-o-w-t-hho rmone
Album-itno-creatirnaitn-ie-o- ---------------------------<-3-0-I g-J/-m-g GHRH- -------------------g--r--o--w--t-hh-o rmone-regl heoarsmionne
8 ESAP2 015
Gn R -H- --------------------------g-o-n-a-d-o-t-ir-nro epeia sinhgo rmone
hCG -------------------------------hu-m-a-n-c -ho-r-iongiocn adotropin
HDL- -------------------------------------------hi-g--hdensiltiyp oprotein
HIV-- --------------------------hu-m-a-n-i -m-m-u-n-o-diecfienvciyr us
HMG-CoAr eductiahnsieb it-o-r- ----3--h-y-d-r-o--3x-ymethylglutaryl
coenzymAe r eductianshei bitor
IGF-1- -----------------------------------i--n--sn-ul-li-igkreo wtfha ct1o r
LDL--- ----------------------------------l--o--wd-e-n-s-i-lt-iy-p -oprotein
LH ----------------------------------------------l--u--t-ei-iznihnogr mone
MCV -----------------------------------m--e--a--nc- o-r-puscular volume
MRI---------------------------------m-a-g-n-e-t-ri-ec-s onanicmea ging
NPH insu-l-i-n- ---------n-e-u-t-rp-ar-lo- t-a-m-Hi-an-gee doirnns ulin
PTH-----------------------------------------------p--a-rhaytroihdo rmone
PTHrP ------------------p--a--r-a-t-h-y-hr-oo-rimdo ne-replraotteedi n
T3 --------------------------------------------------t-ri-io-d-hoy-tr-onine
T4 --------------------------------th-y-r-o-x-i-n-e- ------------------------
TPO antibo-d-i-e-s-----------t-h-y-r-o-p-e-r-o-x-ai-nd-ta-is-be-o dies
TRH- -------------------------------------thyrroopti-rneleashionrgm one
TSH-------------------------------th-y-r-o-t-r-o-p-i-n- ---------------------
VLDL--- -----------------------------v--e--r--ly-o --wdensiltiyp oprotein
9